Foghorn Therapeutics, Inc. (FHTX): Price and Financial Metrics
FHTX Price/Volume Stats
| Current price | $5.30 | 52-week high | $9.97 |
| Prev. close | $5.53 | 52-week low | $2.70 |
| Day low | $5.14 | Volume | 118,100 |
| Day high | $5.94 | Avg. volume | 152,996 |
| 50-day MA | $6.58 | Dividend yield | N/A |
| 200-day MA | $5.92 | Market Cap | 225.60M |
FHTX Stock Price Chart Interactive Chart >
Foghorn Therapeutics, Inc. (FHTX) Company Bio
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Latest FHTX News From Around the Web
Below are the latest news stories about FOGHORN THERAPEUTICS INC that investors may wish to consider to help them evaluate FHTX as an investment opportunity.
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's WhyFoghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual MeetingCAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held |
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Price Is Right But Growth Is Lacking After Shares Rocket 27%Those holding Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares would be relieved that the share price has rebounded 27... |
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsFlagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo |
FHTX Price Returns
| 1-mo | -19.33% |
| 3-mo | 38.02% |
| 6-mo | 71.52% |
| 1-year | -21.13% |
| 3-year | -55.76% |
| 5-year | N/A |
| YTD | -17.83% |
| 2023 | 1.10% |
| 2022 | -72.10% |
| 2021 | 12.83% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...